Pioglitazone Decreases Plasma Cholesteryl Ester Transfer Protein Mass, Associated with a Decrease in Hepatic Triglyceride Content, in Patients with Type 2 Diabetes

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2010 Feb 13

PMID 20150294

Citations 7

Authors

Jacqueline T Jonker

Yanan Wang

Willeke de Haan

Michaela Diamant

Luuk J Rijzewijk

Rutger W van der Meer

Hildo J Lamb

Jouke T Tamsma

Albert de Roos

Johannes A Romijn

Patrick C N Rensen

Johannes W A Smit

Affiliations

Soon will be listed here.

Abstract

Objective: Thiazolidinediones reduce hepatic steatosis and increase HDL cholesterol levels. In mice with human-like lipoprotein metabolism (APOE*3-Leiden.CETP transgenic mice), a decrease in hepatic triglyceride content is associated with a decrease in plasma cholesteryl ester transfer protein (CETP) mass and an increase in HDL levels. Therefore, the aim of the present study was to assess the effects of pioglitazone on CETP mass in patients with type 2 diabetes.

Research Design And Methods: We included 78 men with type 2 diabetes (aged 56.5 +/- 0.6 years; HbA1c 7.1 +/- 0.1%) who were randomly assigned to treatment with pioglitazone (30 mg/day) or metformin (2000 mg/day) and matching placebo, in addition to glimepiride. At baseline and after 24 weeks of treatment plasma HDL cholesterol levels and CETP mass were measured, and hepatic triglyceride content was assessed by proton magnetic resonance spectroscopy. RESULTS Pioglitazone decreased hepatic triglyceride content (5.9 [interquartile range 2.6-17.4] versus 4.1 [1.9-12.3]%, P < 0.05), decreased plasma CETP mass (2.33 +/- 0.10 vs. 2.06 +/- 0.10 microg/ml, P < 0.05), and increased plasma HDL cholesterol level (1.22 +/- 0.05 vs. 1.34 +/- 0.05 mmol/l, P < 0.05). Metformin did not significantly change any of these parameters.

Conclusions: A decrease in hepatic triglyceride content by pioglitazone is accompanied by a decrease in plasma CETP mass and associated with an increase in HDL cholesterol levels. These results in patients with type 2 diabetes fully confirm recent findings in mice.

Citing Articles

Metabolite profiles of diabetes mellitus and response to intervention in anti-hyperglycemic drugs.

Liu Y, Wang D, Liu Y Front Endocrinol (Lausanne). 2023; 14:1237934.

PMID: 38027178 PMC: 10644798. DOI: 10.3389/fendo.2023.1237934.

Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis.

Malandris K, Papandreou S, Avgerinos I, Karagiannis T, Paschos P, Michailidis T Hormones (Athens). 2023; 22(4):655-664.

PMID: 37770761 PMC: 10651545. DOI: 10.1007/s42000-023-00493-z.

Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.

van Eyk H, Blauw L, Bizino M, Wang Y, Willems van Dijk K, de Mutsert R Sci Rep. 2019; 9(1):9996.

PMID: 31292457 PMC: 6620358. DOI: 10.1038/s41598-019-45593-2.

A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia.

Cayo M, Mallanna S, Di Furio F, Jing R, Tolliver L, Bures M Cell Stem Cell. 2017; 20(4):478-489.e5.

PMID: 28388428 PMC: 5385853. DOI: 10.1016/j.stem.2017.01.011.

Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association.

Shimada A, Kimura H, Oida K, Kanehara H, Bando Y, Sakamoto S Lipids Health Dis. 2016; 15:57.

PMID: 26984517 PMC: 4794860. DOI: 10.1186/s12944-016-0223-6.

References

Juvet L, Andresen S, Schuster G, Dalen K, Tobin K, Hollung K . On the role of liver X receptors in lipid accumulation in adipocytes. Mol Endocrinol. 2003; 17(2):172-82. DOI: 10.1210/me.2001-0210. View

Luo Y, Tall A . Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest. 2000; 105(4):513-20. PMC: 289164. DOI: 10.1172/JCI8573. View

van der Hoogt C, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie G, Romijn J . Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res. 2007; 48(8):1763-71. DOI: 10.1194/jlr.M700108-JLR200. View

Targher G, Arcaro G . Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2006; 191(2):235-40. DOI: 10.1016/j.atherosclerosis.2006.08.021. View

Toledo F, Sniderman A, Kelley D . Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care. 2006; 29(8):1845-50. DOI: 10.2337/dc06-0455. View

Yki-Jarvinen H . Thiazolidinediones. N Engl J Med. 2004; 351(11):1106-18. DOI: 10.1056/NEJMra041001. View

Betteridge D, Verges B . Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia. 2005; 48(12):2477-81. DOI: 10.1007/s00125-005-0034-1. View

de Haan W, van der Hoogt C, Westerterp M, Hoekstra M, Dallinga-Thie G, Princen H . Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis. 2007; 197(1):57-63. DOI: 10.1016/j.atherosclerosis.2007.08.001. View

Chappuis B, Braun M, Stettler C, Allemann S, Diem P, Lumb P . Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev. 2007; 23(5):392-9. DOI: 10.1002/dmrr.715. View

10.

Kinoshita M, Teramoto T, Shimazu N, Kaneko K, Ohta M, Koike T . CETP is a determinant of serum LDL-cholesterol but not HDL-cholesterol in healthy Japanese. Atherosclerosis. 1996; 120(1-2):75-82. DOI: 10.1016/0021-9150(95)05684-x. View

11.

van der Meer R, Rijzewijk L, W A M de Jong H, Lamb H, Lubberink M, Romijn J . Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009; 119(15):2069-77. DOI: 10.1161/CIRCULATIONAHA.108.803916. View

12.

Goldberg R, Kendall D, Deeg M, Buse J, Zagar A, Pinaire J . A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28(7):1547-54. DOI: 10.2337/diacare.28.7.1547. View

13.

Szczepaniak L, Nurenberg P, Leonard D, Browning J, Reingold J, Grundy S . Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2004; 288(2):E462-8. DOI: 10.1152/ajpendo.00064.2004. View

14.

Derosa G, Cicero A, DAngelo A, Gaddi A, Ciccarelli L, Piccinni M . Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind,.... Clin Ther. 2006; 28(5):679-88. DOI: 10.1016/j.clinthera.2006.05.012. View

15.

Jeppesen J, Zhou M, Chen Y, Reaven G . Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994; 17(10):1093-9. DOI: 10.2337/diacare.17.10.1093. View

16.

van der Hoorn J, de Haan W, Berbee J, Havekes L, Jukema J, Rensen P . Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol. 2008; 28(11):2016-22. DOI: 10.1161/ATVBAHA.108.171363. View

17.

Radeau T, Robb M, Lau P, Borthwick J, McPherson R . Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man. Atherosclerosis. 1998; 139(2):369-76. DOI: 10.1016/s0021-9150(98)00051-3. View

18.

van der Meer R, Hammer S, Smit J, Frolich M, Bax J, Diamant M . Short-term caloric restriction induces accumulation of myocardial triglycerides and decreases left ventricular diastolic function in healthy subjects. Diabetes. 2007; 56(12):2849-53. DOI: 10.2337/db07-0768. View